{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T01:48:14Z","timestamp":1764812894985,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Icahn School of Medicine"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 DK083909"],"award-info":[{"award-number":["U54 DK083909"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ymgme.2019.01.007","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T02:34:13Z","timestamp":1547778853000},"page":"332-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies"],"prefix":"10.1016","volume":"128","author":[{"given":"Makiko","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Desnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.01.007_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"2961","article-title":"Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias","author":"Anderson","year":"2001"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0015","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMra1608634","volume":"377","author":"Bissell","year":"2017","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0020","first-page":"1005","article-title":"A mouse model of hereditary coproporphyria identified in an ENU mutagenesis screen","volume":"10","author":"Conway","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0025","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1172\/JCI115491","article-title":"Erythropoietic protoporphyria in the house mouseA recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease","volume":"88","author":"Tutois","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0030","first-page":"275","article-title":"The disruption of mouse uroporphyrinogen III synthase (uros) gene is fully lethal","volume":"2","author":"Bensidhoum","year":"1998","journal-title":"Transgenics"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ng0296-195","article-title":"Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria","volume":"12","author":"Lindberg","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0040","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2001-12-0283","article-title":"An exon 10 deletion in the mouse ferrochelatase gene has a dominant-negative effect and causes mild protoporphyria","volume":"100","author":"Magness","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2119\/molmed.2010.00038","article-title":"Feline congenital erythropoietic porphyria: two homozygous UROS missense mutations cause the enzyme deficiency and porphyrin accumulation","volume":"16","author":"Clavero","year":"2010","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0050","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/hmg\/ddp525","article-title":"Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations","volume":"19","author":"Clavero","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1126\/science.905823","article-title":"Bovine protoporphyria: the first nonhuman model of this hereditary photosensitizing disease","volume":"198","author":"Ruth","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0060","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/1523-1747.ep12598357","article-title":"Mouse model for protoporphyria. I. The liver and hepatic protoporphyrin crystals","volume":"65","author":"Gschnait","year":"1975","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0065","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/j.0022-202X.2004.22601.x","article-title":"In vivo oxygen radical generation in the skin of the protoporphyria model mouse with visible light exposure: an L-band ESR study","volume":"122","author":"Takeshita","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0070","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1172\/JCI5986","article-title":"Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria","volume":"103","author":"Lindberg","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2007-1007139","article-title":"Acute porphyrias: pathogenesis of neurological manifestations","volume":"18","author":"Meyer","year":"1998","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0891-5849(95)02035-7","article-title":"The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatric manifestations in porphyrias","volume":"20","author":"Demasi","year":"1996","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0085","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1111\/j.1471-4159.2008.05552.x","article-title":"The heme precursor delta-aminolevulinate blocks peripheral myelin formation","volume":"106","author":"Felitsyn","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0378-4274(97)03887-3","article-title":"Pro-oxidant effects of delta-aminolevulinic acid (delta-ALA) on Chinese hamster ovary (CHO) cells","volume":"91","author":"Neal","year":"1997","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0095","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.abb.2004.09.030","article-title":"Mitochondrial and nuclear DNA damage induced by 5-aminolevulinic acid","volume":"432","author":"Onuki","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(04)15646-8","article-title":"Liver transplantation as a cure for acute intermittent porphyria","volume":"363","author":"Soonawalla","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7326\/0003-4819-154-8-201104190-00015","article-title":"Liver transplantation from donors with acute intermittent porphyria","volume":"154","author":"Dowman","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0110","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/archneur.61.11.1764","article-title":"Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias","volume":"61","author":"Solis","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2119\/molmed.2015.00099","article-title":"Liver transplantation for acute intermittent porphyria: biochemical and pathologic studies of the explanted liver","volume":"21","author":"Yasuda","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0120","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1073\/pnas.1406228111","article-title":"RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice","volume":"111","author":"Yasuda","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0125","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1515\/BC.2005.132","article-title":"Cytosolic persistence of mouse brain CYP1A1 in chronic heme deficiency","volume":"386","author":"Meyer","year":"2005","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.biocel.2014.03.032","article-title":"Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model","volume":"51","author":"Homedan","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0135","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1093\/hmg\/ddv222","article-title":"Mitochondrial energetic defects in muscle and brain of a Hmbs\u2212\/\u2212 mouse model of acute intermittent porphyria","volume":"24","author":"Homedan","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jprot.2015.05.004","article-title":"Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria","volume":"127","author":"Serrano-Mendioroz","year":"2015","journal-title":"J. Proteome"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0145","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.bbagen.2018.02.013","article-title":"Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs","volume":"1862","author":"Ruspini","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0150","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/hmg\/ddw013","article-title":"Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency","volume":"25","author":"Collantes","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0155","first-page":"1050","article-title":"Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools","volume":"86","author":"Bonkovsky","year":"1991","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM198607243150406","article-title":"Instability of hematin used in the treatment of acute hepatic porphyria","volume":"315","author":"Goetsch","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0165","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3727\/096368913X666980","article-title":"Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria","volume":"23","author":"Yin","year":"2014","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ymthe.2004.05.018","article-title":"Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria","volume":"10","author":"Johansson","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0175","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1093\/hmg\/ddt148","article-title":"Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice","volume":"22","author":"Unzu","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0180","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2010.210","article-title":"Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice","volume":"19","author":"Unzu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/mt.2009.250","article-title":"AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function","volume":"18","author":"Yasuda","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0190","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","article-title":"Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria","volume":"65","author":"D'Avola","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0195","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1093\/hmg\/ddy283","article-title":"Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria","volume":"27","author":"Serrano-Mendioroz","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0200","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1089\/hum.2017.056","article-title":"An inducible promoter responsive to different porphyrinogenic stimuli improves gene therapy vectors for acute intermittent porphyria","volume":"29","author":"Serrano-Mendioroz","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0205","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1073\/pnas.0401845101","article-title":"Identification of the xenosensors regulating human 5-aminolevulinate synthase","volume":"101","author":"Podvinec","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0210","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1038\/mtna.2015.36","article-title":"Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification","volume":"4","author":"Chan","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymgme.2019.01.007_bb9092","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0215","first-page":"71","article-title":"A mouse model for South African (R59W) variegate porphyria: construction and initial characterization","volume":"48","author":"Medlock","year":"2002","journal-title":"Cell Mol. Biol. (Noisy-le-grand)"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0220","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/BF01799566","article-title":"A retrospective study of a patient with homozygous form of acute intermittent porphyria","volume":"13","author":"Beukeveld","year":"1990","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0225","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/000456329903600522","article-title":"Compound heterozygous hereditary coproporphyria with fluorescing teeth","volume":"36","author":"Doss","year":"1999","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0230","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(77)90386-5","article-title":"Homozygous case of hereditary coproporphyria","volume":"2","author":"Grandchamp","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0235","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10545-010-9237-9","article-title":"Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R","volume":"34","author":"Hasanoglu","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0240","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/pgmj.69.816.781","article-title":"Homozygous variegate porphyria: an evolving clinical syndrome","volume":"69","author":"Hift","year":"1993","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0245","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00207051","article-title":"Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene","volume":"89","author":"Llewellyn","year":"1992","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0250","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF01799567","article-title":"Identification of the mutations in the parents of a patient with a putative compound heterozygosity for acute intermittent porphyria","volume":"13","author":"Picat","year":"1990","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0260","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddz003","article-title":"Homozygous hydroxymethylbilane synthase knockout mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria","author":"Yasuda","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2119\/molmed.2010.00130","article-title":"CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda","volume":"17","author":"Wickliffe","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0270","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1073\/pnas.98.1.259","article-title":"A mouse model of familial porphyria cutanea tarda","volume":"98","author":"Phillips","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0275","first-page":"449","article-title":"Porphyrinogenic effect of hexachlorobenzene and 2,3,7,8-tetrachlorodibenzo-para-dioxin: is an inhibitor involved in uroporphyrinogen decarboxylase inactivation?","author":"Cantoni","year":"1986","journal-title":"IARC Sci. Publ."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0280","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(85)90287-9","article-title":"Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda","volume":"2","author":"Elder","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0285","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1053\/jhep.2002.35621","article-title":"Uroporphyria in the uroporphyrinogen decarboxylase-deficient mouse: Interplay with siderosis and polychlorinated biphenyl exposure","volume":"36","author":"Franklin","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0290","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1042\/bj2460221","article-title":"Chemically-induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload","volume":"246","author":"Smith","year":"1987","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0295","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1073\/pnas.0700547104","article-title":"A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda","volume":"104","author":"Phillips","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0300","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1469-1809.1998.6230225.x","article-title":"C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria","volume":"62","author":"Frank","year":"1998","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0305","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ygeno.2005.08.018","article-title":"A knock-in mouse model of congenital erythropoietic porphyria","volume":"87","author":"Ged","year":"2006","journal-title":"Genomics"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0310","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2119\/molmed.2010.00258","article-title":"Congenital erythropoietic porphyria: characterization of murine models of the severe common (C73R\/C73R) and later-onset genotypes","volume":"17","author":"Bishop","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0315","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM198604173141607","article-title":"Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions","volume":"314","author":"Piomelli","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0320","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajhg.2007.09.007","article-title":"Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells","volume":"82","author":"Robert-Richard","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0325","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3324\/haematol.2016.151621","article-title":"Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from Gunther disease model","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0330","doi-asserted-by":"crossref","first-page":"18238","DOI":"10.1073\/pnas.1314177110","article-title":"Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria","volume":"110","author":"Blouin","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0335","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7467","article-title":"Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria","volume":"10","author":"Urquiza","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0340","first-page":"471","article-title":"Advances in the understanding of mechanisms and therapeutic use of bortezomib","volume":"12","author":"Mujtaba","year":"2011","journal-title":"Discov. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0345","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00280-017-3489-0","article-title":"Positioning of proteasome inhibitors in therapy of solid malignancies","volume":"81","author":"Roeten","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-4-19","article-title":"Erythropoietic protoporphyria","volume":"4","author":"Lecha","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0355","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.3748\/wjg.v16.i36.4526","article-title":"Liver disease and erythropoietic protoporphyria: a concise review","volume":"16","author":"Casanova-Gonzalez","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0360","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1006\/geno.1993.1242","article-title":"Ferrochelatase structural mutant (Fechm1Pas) in the house mouse","volume":"16","author":"Boulechfar","year":"1993","journal-title":"Genomics"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-2275(20)32334-8","article-title":"Hyperlipidemia and atherosclerosis associated with liver disease in ferrochelatase-deficient mice","volume":"42","author":"Bloks","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0370","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/path.1257","article-title":"Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria","volume":"199","author":"Libbrecht","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0375","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1053\/j.gastro.2011.06.078","article-title":"Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model","volume":"141","author":"Lyoumi","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0380","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1023\/A:1005317124985","article-title":"Erythropoietic protoporphyria","volume":"20","author":"Cox","year":"1997","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0385","first-page":"79","article-title":"Erythropoietic protoporphyria. An overview with emphasis on the liver","author":"Meerman","year":"2000","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0390","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0016-5085(99)70464-6","article-title":"Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria","volume":"117","author":"Meerman","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0395","doi-asserted-by":"crossref","first-page":"G1208","DOI":"10.1152\/ajpgi.00505.2004","article-title":"A mouse model provides evidence that genetic background modulates anemia and liver injury in erythropoietic protoporphyria","volume":"288","author":"Abitbol","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0400","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1172\/JCI24141","article-title":"Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia","volume":"115","author":"Han","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0405","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-105-1-27","article-title":"Iron therapy for hepatic dysfunction in erythropoietic protoporphyria","volume":"105","author":"Gordeuk","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0410","first-page":"610","article-title":"Erythropoietic protoporphyria provoked by iron therapy","volume":"64","author":"Baker","year":"1971","journal-title":"Proc. R. Soc. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0415","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2133.1990.tb08293.x","article-title":"Erythropoietic protoporphyria and iron therapy","volume":"122","author":"McClements","year":"1990","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0420","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2133.1988.tb07102.x","article-title":"Erythropoietic protoporphyria exacerbated by oral iron therapy","volume":"119","author":"Milligan","year":"1988","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0425","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood-2006-04-014142","article-title":"Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice","volume":"109","author":"Lyoumi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0430","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0435","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/jhep.2000.8531","article-title":"Reversion of hepatobiliary alterations By bone marrow transplantation in a murine model of erythropoietic protoporphyria","volume":"32","author":"Fontanellas","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgme.2019.01.007_bb0440","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jhep.2010.09.029","article-title":"Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria","volume":"55","author":"Duchartre","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0445","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1521-2254(199909\/10)1:5<322::AID-JGM53>3.0.CO;2-2","article-title":"Fluorescence-based selection of retrovirally transduced cells in congenital erythropoietic porphyria: direct selection based on the expression of the therapeutic gene","volume":"1","author":"Fontanellas","year":"1999","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0450","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/10488","article-title":"Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy","volume":"5","author":"Pawliuk","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0455","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/mthe.2001.0467","article-title":"Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection","volume":"4","author":"Richard","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0460","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/sj.gt.3302335","article-title":"Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection","volume":"11","author":"Richard","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgme.2019.01.007_bb0465","first-page":"225","article-title":"Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice","volume":"10","author":"Barman-Aksozen","year":"2017","journal-title":"Dis. Model. Mech."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218306486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218306486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:25:30Z","timestamp":1761089130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218306486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1096719218306486"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.01.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}